Nickel(II) bis(benzimidazolin-2-ylidene) complexes of the general formula [NiBr2(NHC)2] (NHC = 1,3-dibenzylbenzimidazolin-2-ylidene, 7; NHC = 1,3-diisopropylbenzimidazolin-2-ylidene, 8; NHC = 1,3-dibenzhydrylbenzimidazolin-2-ylidene, 9; NHC = 1,3-diisobutylbenzimidazolin-2-ylidene, 10; NHC = 1-isopropyl-3-benzylbenzimidazolin-2-ylidene, 11; NHC = 1-benzhydryl-3-benzylbenzimidazolin-2-ylidene, 12) have been prepared and fully characterized by spectroscopic methods and single-crystal X-ray structure analyses. All complexes adopt a square-planar geometry with nickel as the crystallographic inversion center and a trans arrangement of the carbene ligands. For complexes 11 and 12, bearing unsymmetrically substituted ligands, only the trans-anti configuration was found in the solid state. In addition, the structures of 8, 9, 11, and 12 reveal a fixed orientation of the N-isopropyl and N-benzhydryl substituents with the C−H groups pointing to the nickel(II) center to maximize rare intramolecular C−H···Ni anagostic or preagostic interactions. The large downfield shift of these C−H protons in the 1H NMR spectrum compared to their precursor salts indicates that these interactions are retained in solution. Preliminary catalytic studies show that complexes 7−12 are active in the Ullmann coupling of bromobenzene and 4-bromoanisole. In particular, complexes 8, 9, and 12, with sterically more demanding ligands, exhibit the best catalytic activities. The coupling reaction was found to be successful when carried out in neat [Bu4N]Br as ionic liquid, but not in dry DMF or in DMF with [Bu4N]Br as an additive.

Curcumin (CUR) has antioxidant and anti-inflammatory effects that are beneficial to Alzheimer's disease (AD). However, the poor solubility and high instability of CUR compromise its application greatly. In this study, CUR-encapsulated chitosan-coated poly (lactic-co-glycolic acid) nanoparticles (CUR-CS-PLGA-NPs) and hydroxypropyl-β-cyclodextrin-encapsulated CUR complexes (CUR/HP-β-CD inclusion complexes) were developed and compared through intranasal administration. In vitro studies indicated that CUR in CUR/HP-β-CD inclusion complexes was stable under physiological conditions over 72 h with 95.41 ± 0.01% remaining, which was higher than 49.66 ± 3.91% remaining in CUR-CS-PLGA-NPs. Meanwhile, CUR/HP-β-CD inclusion complexes showed a higher cellular uptake level of CUR than CUR-CS-PLGA-NPs in SH-SY5Y cells. Both formulations could reduce CUR's cellular cytotoxicity and showed a comparable antioxidant effect. Both formulations displayed the anti-inflammatory effect at 20 μM CUR in BV-2 cells, which decreased TNF-α and IL-6 levels to approximately 70 and 40%, respectively, when compared to the positive control, respectively. In vivo pharmacokinetic studies indicated that after intranasal administration, the AUC values of CUR in the plasma and brain of the CUR/HP-β-CD inclusion complex group were 2.57-fold and 1.12-fold higher than those in the CUR-CS-PLGA-NP group at the same dose of 2 mg/kg, respectively. In conclusion, CUR/HP-β-CD inclusion complexes displayed better properties than CUR-CS-PLGA-NPs as a carrier for intranasal delivery of CUR for application in AD.

Objectives R-flurbiprofen (R-FP) was found to offer neuroprotective effects by inhibiting mitochondrial calcium overload induced by b-amyloid peptide toxicity in Alzheimer's disease (AD). However, poor brain penetration after oral administration posed a challenge to its further development for AD treatment. In this study, we investigated the potential of serum albumin as nanoparticulate carriers for nose-to-brain delivery of R-FP to improve its brain accumulation. Methods Mice were subjected to three treatment groups: (1) intranasal R-FP solution, (2) oral R-FP solution and (3) intranasal R-FP albumin nanoparticles. We also investigated whether the in-vivo R-FP level achieved in the brain afforded by intranasal administration of R-FP nanoparticles had any effect on mitochondrial respiratory activity in an in-vitro AD model. Key findings Our in-vivo experiments demonstrate that the intranasal administration of serum albumin-based R-FP nanoparticles achieved higher brainto-plasma ratio profile as compared to intranasal and oral administration of a simple R-FP solution. We observed significantly improved basal and maximal mitochondrial respiration in cells treated with R-FP albumin nanoparticles at in-vivo brain concentration. Conclusions Serum albumin-based nanoparticles administered via the nasal route may be a viable approach in delivering therapeutic agents to the brain to alleviate mitochondrial dysfunction in AD.

No abstract

No abstract

Accumulating evidence suggests that disruptions in brain energy metabolism may be a key player in the pathogenesis of Alzheimer’s disease (AD). Pioglitazone (PIO) has been found to exert beneficial effects on metabolic dysfunction in many AD preclinical studies. However, limited success in clinical trials remains an obstacle to its development for the treatment of AD. PIO’s poor brain penetration was often cited as a contributing factor to the lack of clinical benefit. In this study, we prepared PIO-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles and administered them as suspended nanoparticles via nebulization. Preliminary investigation of drug distribution to the brain revealed comparatively reduced systemic exposure after administering PIO nanoparticles via the intranasal route. In vitro, extracellular flux analysis showed significantly raised spare respiratory capacity when cells were treated with low-dose PIO nanoparticles. Tg2576 transgenic mice treated with low-dose PIO nanoparticles over four months exhibited an overall trend of reduced hyperactivity in open field tests but did not show any visible effect on alternation rates in the Y-maze task. Subsequent 1H NMR-based metabolic profiling of their plasma and different brain regions revealed differences in metabolic profiles in the cerebellum, cortex, and hippocampus of Tg2576 mice after long-term PIO treatment, but not in their midbrain and plasma. In particular, the specificity of PIO’s treatment effects on perturbed amino acid metabolism was observed in the cortex of transgenic mice with increases in alanine and N-acetylaspartate levels, supporting the notion that PIO treatment exerts beneficial effects on impaired energy metabolism associated with AD. In conclusion, inhalation exposure to PIO nanoparticles presents an exciting opportunity that this drug could be administered intranasally at a much lower dose while achieving a sufficient level in the brain to elicit metabolic benefits at an early stage of AD but with reduced systemic exposure.

No abstract